Market closedNon-fractional
Eliem Therapeutics/ELYM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Eliem Therapeutics
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its main drug candidate is ETX-155 for major depressive disorder (MDD) and focal onset seizures (FOS).
Ticker
ELYM
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Wilmington, United States
Employees
10
Website
eliemtx.com
ELYM Metrics
BasicAdvanced
$594M
Market cap
-
P/E ratio
-$0.53
EPS
-0.33
Beta
-
Dividend rate
Price and volume
Market cap
$594M
Beta
-0.33
Financial strength
Current ratio
37.025
Quick ratio
36.289
Total debt to equity
0.211
Management effectiveness
Return on assets (TTM)
-9.09%
Return on equity (TTM)
-13.01%
Valuation
Price to book
2.31
Price to tangible book (TTM)
2.31
Price to free cash flow (TTM)
-33.522
Growth
Earnings per share change (TTM)
-74.15%
3-year earnings per share growth (CAGR)
-67.54%
ELYM Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$1.6M
-55.56%
Profit margin
0.00%
NaN%
ELYM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 22
Q3 22
Q4 22
Q1 23
Actual
-$0.56
-$0.37
-$0.29
-$0.25
Expected
-$0.47
-
-
-
Surprise
20.00%
-
-
-
ELYM News
AllArticlesVideos
Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
Seeking Alpha·4 weeks ago
Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes
GlobeNewsWire·4 weeks ago
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Eliem Therapeutics stock?
Eliem Therapeutics (ELYM) has a market cap of $594M as of July 27, 2024.
What is the P/E ratio for Eliem Therapeutics stock?
The price to earnings (P/E) ratio for Eliem Therapeutics (ELYM) stock is 0 as of July 27, 2024.
Does Eliem Therapeutics stock pay dividends?
No, Eliem Therapeutics (ELYM) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Eliem Therapeutics dividend payment date?
Eliem Therapeutics (ELYM) stock does not pay dividends to its shareholders.
What is the beta indicator for Eliem Therapeutics?
Eliem Therapeutics (ELYM) has a beta rating of -0.33. This means that it has an inverse relation to market volatility.
Buy or sell Eliem Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.